Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, PureTech Health's Enterprise Value is $167.75 Mil.
PureTech Health's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-65.15 Mil. Therefore, PureTech Health's EV-to-EBIT ratio for today is -2.57.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, PureTech Health's Enterprise Value is $167.75 Mil.
PureTech Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-61.80 Mil. Therefore, PureTech Health's EV-to-EBITDA ratio for today is -2.71.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, PureTech Health's Enterprise Value is $167.75 Mil.
PureTech Health's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $4.66 Mil. Therefore, PureTech Health's EV-to-Revenue ratio for today is 36.01.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, PureTech Health's Enterprise Value is $167.75 Mil.
PureTech Health's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-85.13 Mil. Therefore, PureTech Health's EV-to-FCF ratio for today is -1.97.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
PureTech Health (OTCPK:PRTCY) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
PureTech Health's current Enterprise Value is $167.75 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. PureTech Health's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-65.15 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
PureTech Health's current Enterprise Value is $167.75 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. PureTech Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-61.80 Mil.
PureTech Health's current Enterprise Value is $167.75 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. PureTech Health's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $4.66 Mil.
PureTech Health's current Enterprise Value is $167.75 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. PureTech Health's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-85.13 Mil.
PureTech Health's current Enterprise Value is $167.75 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. PureTech Health's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-85.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PureTech Health Enterprise Value Related Terms
PureTech Health Enterprise Value Historical Data
* Premium members only.
The historical data trend for PureTech Health's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRTCY vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, PureTech Health's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PureTech Health Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PureTech Health's Enterprise Value distribution charts can be found below:
* The bar in red indicates where PureTech Health's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
PureTech Health's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PureTech Health (PRTCY) has a Enterprise Value of $167.75 Mil as of Jun. 24, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on PureTech Health and its competitors.
Is PureTech Health's Enterprise Value too high?
PureTech Health's current Enterprise Value is $167.75 Mil. Overall, PureTech Health has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's Enterprise Value compare to VRTX and REGN?
PureTech Health's Enterprise Value of $167.75 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on PureTech Health and its competitors. PureTech Health's current Enterprise Value is $167.75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (PRTCY) is currently considered Possible Value Trap. The stock's GF Value™ is $70.09, compared to a current price of $17.54 — trading 75% below its estimated fair value. The current Enterprise Value is $167.75 Mil. PureTech Health's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For PureTech Health (PRTCY), the current Enterprise Value is $167.75 Mil as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PureTech Health (PRTCY) Overvalued in 2026?
Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued.
The current stock price of $17.54 is trading 75% below its estimated GF Value™ of $70.09.
GuruFocus considers PureTech Health to be Possible Value Trap.
Key valuation signals for PRTCY:
Enterprise Value: $167.75 Mil
GF Value™: $70.09 vs. price of $17.54 (75% below fair value)
No single metric tells the full story. See the PRTCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
62GF Score
Get the complete analysis for PRTCY
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRTCY has been successfully added to your 
